C4 Therapeutics Inc
CCCCHealthcare|Biotechnology|USA
$4.06
-0.23 (-5.36%)
Tangible Book
$2.25
Upcoming Data Readouts (3)
Sep 2026
Est. completion
P1Multiple Myeloma
Study to Assess the Safety and Tolerability of CFT7455 in Relapsed/Refractory Non-Hodgkin's Lymphoma or Multiple Myeloma
NCT04756726n=224
Dec 2028
Est. completion
P1Multiple Myeloma (MM)
A Study to Learn About the Effects of Cemsidomide in Combination With Elranatamab in Relapsed/Refractory Multiple Myeloma Subjects
NCT07280013n=60
Mar 2030
Est. completion
P2Multiple Myeloma
A Study to Evaluate the Efficacy of Cemsidomide + Dexamethasone in Participants With Relapsed/Refractory Multiple Myeloma
NCT07284758n=100